|Cancer Stem Cell News 5.21 June 1, 2016|
Investigators found that long noncoding RNA (lncRNA)-β-Catm is required for self-renewal of liver cancer stem cells (CSCs) and tumor propagation in mice. lnc-β-Catm associates with β-catenin and the methyltransferase EZH2, thereby promoting β-catenin methylation. [Nat Struct Mol Biol]
Epithelial Cell Adhesion Molecule (EpCAM) is a Polycomb Repressive Complex 2-repressed gene, normally expressed in hepatic progenitors, but re-expressed in hepatic cancer stem cells. The authors investigated the functional significance of EpCAM re-expression in hepatitis B virus-mediated hepatocarcinogenesis. [J Hepatol]
Investigators analyzed the role of prion protein (PrPC) in glioblastoma (GBM) cell pathogenicity focusing on tumor-initiating cells, the subpopulation responsible for development, progression and recurrence of most malignancies. Analyzing four GBM cancer stem cell-enriched cultures, they showed that PrPC expression is directly correlated with the proliferation rate of the cells. [Oncotarget]
The present work sought to investigate the multipotent and mesenchymal properties of primary highly purified human CD133+ glioblastoma-initiating cells. [Oncotarget]
Scientists investigate the mechanism of action responsible for the induction of apoptosis by disulfiram/copper and its effect on cancer stem cell properties in HER2-positive breast cancers in vitro and in vivo. [Cancer Lett]
Researchers found that ovarian cancer cells significantly acquired the expression of epithelial-to-mesenchymal transition and cancer stem cells markers and a remarkable chemoresistance to clinically relevant doses of frontline chemotherapeutic drugs cisplatin and paclitaxel when grown under fluid shear stress, which corroborates with the physiological attainable levels in the malignant ascites, but not under static condition. [Sci Rep]
To characterize the contributions of Dickkopf-1 towards the induction of vasculogenic mimicry in non-small cell lung cancer, the authors evaluated cohorts of primary tumors, performed in vitro functional studies and generated xenograft mouse models. [J Cell Mol Med]
Sphere formation in conditioned serum-free culture medium supplemented with epidermal growth factor and basic fibroblast growth factor (tumorospheres) is considered useful for the enrichment of cancer stem-like cells, which are also known as tumor initiating cells. Researchers used an Agilent Gene Expression microarray to investigate the gene expression profile of melanoma cancer stem-like cells. [Cancer Sci]
Investigators confirmed that ALDH1 positivity is the best marker for the identification of breast cancer stem cells in BRCA1-defective breast cancer cell lines when compared to the CD marker profile and Side Population analysis. [BMC Cancer]
Cancer is now viewed as a stem cell disease. There is still no consensus on the metabolic characteristics of cancer stem cells, with several studies indicating that they are mainly glycolytic and others pointing instead to mitochondrial metabolism as their principal source of energy. [Breast Cancer Res]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Resolution Bioscience announced that its Resolution ctDx™ blood-based NGS platform was used to detect ALK fusions, ALK resistance mutations and other driver mutations in patients’ circulating tumor DNA in a Phase I/II clinical trial of the ALK inhibitor X-396 (ensartinib), Xcovery’s lead drug candidate in development for the treatment of ALK-positive non-small cell lung cancer. [Press release from Resolution Bioscience (PR Newswire Association LLC.) discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
|From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.|
PharmaEngine Inc. announced that the first patient has been dosed in a global pivotal Phase II/III trial of PEP503 in soft tissue sarcoma at Perpetual Succour Hospital, Cebu, Philippines. [PharmaEngine Inc.]
Nektar Therapeutics announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar’s investigational drug therapy, ONZEALD, which has completed a Phase III clinical trial in patients with advanced breast cancer. The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe, Switzerland and Turkey. [Nektar Therapeutics]
RegeneRx Biopharmaceuticals, Inc. and Lee’s Pharmaceutical Holdings Ltd. announced acceleration of development of RGN-259 in China. [RegeneRx Biopharmaceuticals, Inc.]
NEW American Association for Cancer Research, Colorectal Cancer: From Initiation to Outcomes
Visit our events page to see a complete list of events in the cancer stem cell community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 5.21 | Jun 1 2016